Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 13, 2000

View Archived Issues

Novartis and Noven enter marketing agreement for transdermal HRT

Company Profile: Naeja

Neurochem seeks U.K. approval to begin Fibrillex phase II/III trial

FDA grants fast track designation for RSR-13

First clinical trial begins for novel HDL therapy

Structural Bioinformatics reports small-molecule PTP1B inhibitors

FDA advises removal of phenylpropanolamine-containing products

Fujisawa continuing zenarestat development in Japan

NeoRx suspends STR trials

Cambridge Drug Discovery signs drug screening agreements with Avidex and RiboTargets

Cubist and Emisphere collaborate on oral delivery of daptomycin

Partnership formed for INOmax distribution in Japan

Novel antitumor compounds act by inhibiting VEGF receptor binding and function

Synthetic MMP inhibitor from Roche has promising antitumor/antiangiogenic activity

NCI-EORTC-AACR news: WP-769, a new oral doxorubicin analogue with an improved biological profile

Gelatinase-selective MMP inhibitor with potential clinical utility in cancer designed at Abbott

Structurally novel antitumor, antimetastatic and antiangiogenic agent with oral efficacy

Synthesis and preclinical evaluation of unique series of antitumor agents reported in Amsterdam

Trimetazidine analogue exerts significant hepatoprotective effects in I/R injury model in rats

First clinical results for UR-9825 discussed at Mycology meeting

Selective cGMP-PDE inhibitors synthesized at Nippon Soda

Novel series of anticoagulants patented by Kissei research team

Metalloproteinase inhibitors described by DuPont as particularly useful for arthritic conditions

Sankyo's new blood glucose-lowering agents described in recent patent

DuPont prepares aryl sulfonyl-based factor Xa inhibitors

Research at Neurogen leads to identification of new B2 receptor modulators

Synthesis and use of new NK3 receptor ligands presented by Neurogen

Shionogi patents several series of gelatinase A inhibitors

Popular Stories

Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...
AA meeting of minds as PTC, Novartis push votoplam in HD
BioWorld
What PTC Therapeutics Inc.’s latest data with votoplam might mean in the Huntington’s disease (HD) landscape became grist for Wall Street after the firm unveiled...
Alceptor Therapeutics discovers new α2B-adrenoceptor agonists
BioWorld Science
Alceptor Therapeutics Inc. has patented new pyrazol-5-amine α2B-adrenoceptor agonists reported to be useful for the treatment of pain and hypertension.
Quintuple GLP-1–GIP–PPAR agonist for obesity and diabetes control
BioWorld
A new molecule combines the action of two incretins, GLP-1 and GIP, hormones that regulate glucose and appetite, with lanifibranor, a triple agonist of peroxisome...